Clarity Capital Partners’s iShares Biotechnology ETF IBB Stock Holding History

Clarity Capital Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,412	Closed	-$206K	–	138
2024 Q3	$206K	Buy	+1,412	New	+$204K	0.12%	114

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Clarity Capital Partners's IBB Position: Q4 2024 in Review

Clarity Capital Partners sold out of iShares Biotechnology ETF (IBB) in Q4 2024, closing a stake of 1,412 shares — an estimated $206K sold.

Clarity Capital Partners first reported a position in IBB in Q3 2024 and held it in 1 quarter. The position peaked at $206K in Q3 2024. 874 funds tracked by Wall St. Rank hold IBB as of Q4 2024.

Clarity Capital Partners reported no remaining iShares Biotechnology ETF position as of Q4 2024 after selling out during the quarter.
Clarity Capital Partners sold 1,412 iShares Biotechnology ETF shares in Q4 2024, an estimated $206K.
Clarity Capital Partners first reported a position in iShares Biotechnology ETF in Q3 2024 and held it in 1 quarter.
Clarity Capital Partners's iShares Biotechnology ETF position peaked at $206K in Q3 2024.
874 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2024.

Based on Clarity Capital Partners's 13F filing for Q4 2024, filed 29 Jan 2025.